Sheharyar Khokhar, MD
Nephrology · Rochester, NYNPI 1093897761
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,700 of the $2,839 with a category attached, or 95.1%. Miach Orthopaedics, Inc. accounts for 88.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $2,551 and has fallen 97.3% since, to $68 in 2025.
Across 31 payments — averaging $91.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Miach Orthopaedics, Inc.$3K
- Vifor Pharma, Inc.$200
- Travere Therapeutics, Inc.$59
- Otsuka America Pharmaceutical, Inc.$33
- Ardelyx, Inc.$29
- Baxter Healthcare$17
What the payments were for
- Speaking & faculty fees$2,70095%
- Food & beverage$803%
- Education$592%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Miach Orthopaedics, Inc. | 1 | $2,500 |
| Vifor Pharma, Inc. | 1 | $200 |
| Travere Therapeutics, Inc. | 26 | $59 |
| Otsuka America Pharmaceutical, Inc. | 1 | $33 |
| Ardelyx, Inc. | 1 | $29 |
| Baxter Healthcare | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$200
How this compares
$2,839 in reported general payments places this provider in the 75th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 43 | $17,507 |
| FarxigaDapagliflozin Propanediol | 18 | $17,109 |
| JardianceEmpagliflozin | 16 | $12,614 |
| ProsolParenteral Amino Acid 20% No.1 | 103 | $12,492 |
| Sevelamer Carbonate | 64 | $11,145 |
| Potassium Citrate ErPotassium Citrate | 48 | $5,261 |
| Clonidine | 22 | $4,586 |
| Calcium Acetate | 33 | $2,519 |
| Torsemide | 149 | $2,435 |
| Amlodipine Besylate | 294 | $1,984 |
| Midodrine Hcl | 31 | $1,961 |
| Labetalol Hcl | 34 | $1,322 |
| Calcitriol | 71 | $1,298 |
| Chlorthalidone | 60 | $1,181 |
| Mycophenolate Mofetil | 14 | $1,105 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Rochester
- Daniel GrayRochester$114K
- Leslie WongRochester$48K
- David BushinskyRochester$44K
- James SloandRochester$33K
- Payam ShakouriPoughkeepsie$930K
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Bruce SpinowitzBronx$465K
- Steven CocaNew York$445K
- Joseph RoglieriTroy$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.